These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 2540920)
21. Flecainide-induced Increase in QRS Duration and Proarrhythmia during Exercise. Bordier P; Garrigue S; Bernard V; Haissaguerre M; Douard H; Broustet JP; Clementy J Clin Drug Investig; 1997 Jun; 13(6):326-37. PubMed ID: 27519494 [TBL] [Abstract][Full Text] [Related]
22. Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. Brugada J; Boersma L; Kirchhof C; Allessie M Circulation; 1991 Oct; 84(4):1808-18. PubMed ID: 1914116 [TBL] [Abstract][Full Text] [Related]
23. Fast and slow blockade of sodium channels by flecainide in rabbit cardiac Purkinje fibres. Konzen G; Reichardt B; Hauswirth O Naunyn Schmiedebergs Arch Pharmacol; 1990 Jun; 341(6):565-76. PubMed ID: 2168022 [TBL] [Abstract][Full Text] [Related]
24. Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Ranger S; Nattel S Circulation; 1995 Sep; 92(5):1300-11. PubMed ID: 7648679 [TBL] [Abstract][Full Text] [Related]
25. Use-dependent electrophysiologic effects of amiodarone in coronary artery disease and inducible ventricular tachycardia. Chiamvimonvat N; Mitchell LB; Gillis AM; Wyse DG; Sheldon RS; Duff HJ Am J Cardiol; 1992 Sep; 70(6):598-604. PubMed ID: 1324598 [TBL] [Abstract][Full Text] [Related]
26. Conduction velocity depression and drug-induced ventricular tachyarrhythmias. Effects of lidocaine in the intact canine heart. Anderson KP; Walker R; Lux RL; Ershler PR; Menlove R; Williams MR; Krall R; Moddrelle D Circulation; 1990 Mar; 81(3):1024-38. PubMed ID: 2155070 [TBL] [Abstract][Full Text] [Related]
27. Flecainide-induced prolongation of ventricular repolarization contributes to the proarrhythmic profile of action. Osadchii OE Int J Cardiol; 2015 Oct; 197():81-2. PubMed ID: 26142191 [No Abstract] [Full Text] [Related]
28. Modulation of flecainide's cardiac sodium channel blocking actions by extracellular sodium: a possible cellular mechanism for the action of sodium salts in flecainide cardiotoxicity. Ranger S; Sheldon R; Fermini B; Nattel S J Pharmacol Exp Ther; 1993 Mar; 264(3):1160-7. PubMed ID: 8383739 [TBL] [Abstract][Full Text] [Related]
29. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Falk RH Ann Intern Med; 1989 Jul; 111(2):107-11. PubMed ID: 2500880 [TBL] [Abstract][Full Text] [Related]
30. Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects. Boriani G; Capucci A; Strocchi E; Calliva R; Santarelli A; Biffi M; Magnani B Int J Clin Pharmacol Res; 1993; 13(4):211-9. PubMed ID: 8150547 [TBL] [Abstract][Full Text] [Related]
31. Electrophysiological and hemodynamic effects of vernakalant and flecainide during cardiac resynchronization in dyssynchronous canine hearts. van Middendorp LB; Strik M; Houthuizen P; Kuiper M; Maessen JG; Auricchio A; Prinzen FW J Cardiovasc Pharmacol; 2014 Jan; 63(1):25-32. PubMed ID: 24084224 [TBL] [Abstract][Full Text] [Related]
32. Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds. Hellestrand KJ; Nathan AW; Bexton RS; Camm AJ Am J Cardiol; 1984 Feb; 53(5):30B-38B. PubMed ID: 6695817 [TBL] [Abstract][Full Text] [Related]
33. The prolongation of QRS-duration resulting from delayed recovery of ventricular excitability. A new mechanism for intraventricular conduction disturbance. A preliminary note. Nagamoto Y; Arita M; Saikawa T Jpn Heart J; 1976 Nov; 17(6):760-1. PubMed ID: 1011369 [TBL] [Abstract][Full Text] [Related]
34. Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. Sakai T; Ogawa S; Hosokawa M; Miyazaki T; Sakurai K; Nakamura Y Cardiovasc Res; 1989 Mar; 23(3):177-83. PubMed ID: 2512008 [TBL] [Abstract][Full Text] [Related]
35. Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide. Kanemoto M; Shimizu A; Yamagata T; Esato M; Ueyama T; Yoshiga Y; Kakugawa H; Kametani R; Inoue N; Sawa A; Matsuzaki M Cardiovasc Drugs Ther; 2004 Jul; 18(4):295-303. PubMed ID: 15367827 [TBL] [Abstract][Full Text] [Related]
36. Characterization of the rate-dependent effects of ethmozine on conduction, in vivo, and on the sodium current, in vitro, in the newborn heart. Liu W; Clarkson CW; Yamasaki S; Chang C; Stolfi A; Pickoff AS J Pharmacol Exp Ther; 1992 Nov; 263(2):608-16. PubMed ID: 1331407 [TBL] [Abstract][Full Text] [Related]
37. Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect. Anastasiou-Nana MI; Anderson JL; Stewart JR; Crevey BJ; Yanowitz FG; Lutz JR; Johnson TA Am Heart J; 1987 May; 113(5):1071-7. PubMed ID: 3107362 [TBL] [Abstract][Full Text] [Related]
38. Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. Lederman SN; Wenger TL; Bolster DE; Strauss HC J Cardiovasc Pharmacol; 1989 Apr; 13(4):541-6. PubMed ID: 2470990 [TBL] [Abstract][Full Text] [Related]
39. Mechanisms underlying increased right ventricular conduction sensitivity to flecainide challenge. Veeraraghavan R; Poelzing S Cardiovasc Res; 2008 Mar; 77(4):749-56. PubMed ID: 18056761 [TBL] [Abstract][Full Text] [Related]
40. Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans. Nademanee K; Stevenson WG; Weiss JN; Frame VB; Antimisiaris MG; Suithichaiyakul T; Pruitt CM Circulation; 1990 Mar; 81(3):790-6. PubMed ID: 2306831 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]